Northway Biotech
24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Maxon Announces Free Tools and Mobile Expansion of ZBrush and Cinema 4D16.4.2026 16:55:00 CEST | Press release
Cinema 4D brings professional 3D workflows to iPad. The return of Autograph - now free for individual users. ZBrush expands to Windows on Arm. See it all at NAB 2026. BAD HOMBURG, GERMANY / ACCESS Newswire / April 16, 2026 / Maxon, a leading developer of powerful and intuitive 2D and 3D software and complete graphic design workflows, today announced a major step forward in its mission to make professional creative tools more accessible to artists everywhere. With the debut of Cinema 4D on iPad, the return of the Autograph motion graphics application, and the expansion of Maxon tools to Windows on Arm (WoA) tablet devices, Maxon is lowering the barrier to entry while empowering artists to work where they want, how they want. Visitors to NAB 2026 can see it all at the Maxon booth (N2741). Professional Tools, Broader Access As demand for 3D and motion content accelerates across social media, streaming, gaming, and immersive media, creators are seeking flexible and affordable entry points
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 202616.4.2026 15:20:00 CEST | Press release
Built on Available Infrastructure's SanQtum AI quantum-resistant edge platform, the 48,000-GPU fleet targets enterprises facing extended GPU lead times - with DataValue®, DataScore®, and Information Data Exchange® (IDE®) tokenization built in PHILADELPHIA, PA / ACCESS Newswire / April 16, 2026 / The global AI compute shortage has forced enterprises outside the hyperscaler customer set to wait extended periods for high-performance GPU capacity. Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the first sites of its new quantum-ready high-performance computing ("HPC") GPU network are now live in New York and Philadelphia, with commercial availability of the full 48,000-GPU fleet beginning in Q3 2026. The fleet will be distributed across 1,000 urban micro-edge neocloud sites in more than 100 U.S. cities by the end of 2026. Each
Camino Corporation Commences Drilling at Costa de Cobre District-Scale IOCG Copper Discovery in Peru16.4.2026 12:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 16, 2026 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce the commencement of a drilling campaign at its Costa de Cobre district-scale IOCG copper discovery in Peru ("Costa de Cobre" or "Copper Coast"), previously referred to as the Los Chapitos copper project(1). Camino has rebranded the Los Chapitos project as the Costa de Cobre, the Copper Coast, to better reflect its low-elevation coastal setting and strategic proximity to key infrastructure, including the proposed San Juan de Marcona Port Terminal, a major new port facility planned approximately 125 km to the north at Marcona. The Costa de Cobre project is advancing to the next stage of exploration and development as the Company enters into a joint venture with Nittetsu Mining Co., Ltd.("Nittetsu"), under which Camino will serve as operator and hold a 65% interest, while Nittetsu will hold the remaining 35% interest. Camino is also d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom